HYDERABAD, India, Feb. 20, 2026 /PRNewswire/ — According to the latest Mordor Intelligence report, the insulin delivery devices market size is estimated at USD 33.79 billion in 2026, and is expected to reach USD 49.23 billion by 2031, at a CAGR of 7.82% during the forecast period (2026-2031), supported by the rising global prevalence of diabetes and increasing demand for advanced insulin administration solutions. The market is expanding as patients and healthcare providers increasingly adopt user-friendly, accurate, and technology-integrated insulin delivery systems to improve glycemic control and enhance quality of life. The insulin delivery devices market growth is closely linked to the growing burden of both type 1 and type 2 diabetes worldwide. With a rising number of patients requiring long-term insulin therapy, demand for efficient and convenient delivery systems such as insulin pens, pumps, and pen needles continues to increase. Healthcare systems are prioritizing improved disease management strategies, which is driving adoption of devices that enable better dosing accuracy, portability, and patient compliance.
Insulin Delivery Devices Market Share by Region
North America represents a leading share of the insulin delivery devices market, driven by a high prevalence of diabetes, strong adoption of advanced diabetes technologies, and well-established reimbursement systems. The region continues to invest in innovative insulin delivery solutions, particularly smart and automated systems that integrate with continuous glucose monitoring platforms.
Europe holds a significant market share, supported by growing awareness programs, structured diabetes management initiatives, and increasing adoption of insulin pens and pumps across clinical and homecare settings.
Asia-Pacific is emerging as a high-growth region due to the rapidly expanding diabetic population, improving access to healthcare services, and increasing affordability of insulin delivery devices.
Insulin Delivery Devices Market Trends & Forecast
Rising Adoption of Insulin Pens and Pumps
Insulin pens and pumps are gaining widespread acceptance due to their convenience, dosing precision, and patient-friendly design. These devices are increasingly preferred over traditional syringes, particularly in homecare settings.
Integration of Smart and Connected Technologies
The incorporation of digital health features, including connectivity with mobile applications and glucose monitoring systems, is enhancing patient engagement and supporting data-driven diabetes management strategies.
Insulin Delivery Devices Industry Segmentation Overview
By Product Type
- Insulin Pens
- Reusable Pens
- Disposable Pens
- Insulin Pumps
- Tethered Pumps
- Patch / Wearable Pumps
- Automated Hybrid Closed-Loop Systems
- Insulin Syringes
- Needle-Free Injectors
- Jet Injectors
- Others
By Technology / Connectivity
- Connected (Bluetooth / NFC)
- Non-Connected / Conventional
By Patient Age Group
- Pediatrics (Less Than 18 yrs)
- Adults (Equal to, More Than 18 yrs)
- Geriatrics (≥65 years+)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Diabetes Clinics & Centers
By End User
- Homecare Settings
- Hospitals & Specialty Clinics
- Ambulatory Surgical Centers
- Others
By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/insulin-delivery-devices-market?utm_source=prnewswire
Insulin Delivery Devices Market Competitive Outlook
The insulin delivery devices market features established medical device manufacturers and specialized diabetes care companies. Market participants are focusing on product innovation, digital integration, and strategic partnerships to strengthen their portfolios and expand geographic presence. Companies are investing in next-generation smart insulin systems and user-centric designs to address evolving patient and provider needs.
Insulin Delivery Devices Companies:
- Becton, Dickinson and Company
- Bigfoot Biomedical
- Biocon Ltd.
- CeQur Corporation
- Debiotech SA
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Insulet Corporation
- Jiangsu Delfu Medical Device Co., Ltd.
- Medtronic plc
- Medtrum Technologies Inc.
- Nipro Corporation
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Sanofi S.A.
- Sooil Development Co., Ltd.
- Tandem Diabetes Care, Inc.
- Terumo Corporation
- Valeritas Holdings, Inc.
- Ypsomed AG
Industry Related Reports by Mordor Intelligence
Renal Denervation Devices Market Size – The renal denervation devices market is expected to register a CAGR of 35.20% during the forecast period. Growth is driven by rising prevalence of resistant hypertension, increasing clinical validation of catheter-based denervation procedures, and growing interest in minimally invasive cardiovascular interventions.
Cardiovascular Devices Market Share – The cardiovascular devices market is estimated to grow from USD 64.71 billion in 2026 to USD 81.29 billion by 2031, registering a CAGR of 4.67% during the forecast period. Market expansion is supported by the increasing burden of cardiovascular diseases, rising demand for interventional procedures, and continued adoption of advanced diagnostic and monitoring devices.
Boston Scientific Corporation, Abbott, Medtronic, Edwards Lifesciences Corporation and Cardinal Health are the major companies operating in this market.
Read more about companies active in the Cardiovascular Devices Market: https://www.mordorintelligence.com/industry-reports/global-cardiovascular-devices-market-industry/companies?utm_source=prnewswire
Diabetic Retinopathy Market Growth – The diabetic retinopathy market is projected to grow from USD 10.71 million in 2026 to USD 14.52 million by 2031, at a CAGR of 6.27% over the forecast period. Growth is driven by the rising global prevalence of diabetes, expanding screening initiatives, and increased use of pharmacological and laser-based treatment options.
Regeneron Pharmaceuticals, Inc., Alimera Sciences, Oxurion NV., Abbvie Inc. and F. Hoffmann-La Roche Ltd are the major companies operating in this market.
Read more about companies active in the Diabetic Retinopathy Market: https://www.mordorintelligence.com/industry-reports/diabetic-retinopathy-market/companies?utm_source=prnewswire
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries, please contact:
[email protected]
https://www.mordorintelligence.com/contact-us
Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg
View original content:
Featured Image: Megapixl @ Natalimis